Oncolytic Virus CF33-expressing hNIS/Anti-PD-L1 Antibody
Phase 1Active 0 watching 0 views this week💤 Quiet
25
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Anatomic Stage IV Breast Cancer AJCC v8
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8
Trial Timeline
Oct 18, 2021 → Mar 30, 2026
NCT ID
NCT05081492About Oncolytic Virus CF33-expressing hNIS/Anti-PD-L1 Antibody
Oncolytic Virus CF33-expressing hNIS/Anti-PD-L1 Antibody is a phase 1 stage product being developed by Imugene for Anatomic Stage IV Breast Cancer AJCC v8. The current trial status is active. This product is registered under clinical trial identifier NCT05081492. Target conditions include Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8.
Hype Score Breakdown
Clinical
10
Activity
5
Company
2
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05081492 | Phase 1 | Active |
Competing Products
13 competing products in Anatomic Stage IV Breast Cancer AJCC v8
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Abemaciclib + Niraparib Tosylate Monohydrate | Eli Lilly | Phase 1 | 33 |
| Capivasertib + Ceralasertib + Durvalumab + Olaparib + Selumetinib | AstraZeneca | Phase 2 | 52 |
| Pembrolizumab + Tamoxifen + Vorinostat | Merck | Phase 2 | 52 |
| Carboplatin + Docetaxel + Fulvestrant + Pertuzumab + Ribociclib + Trastuzumab + Tucatinib | Novartis | Phase 1/2 | 41 |
| Lutetium Lu 177 Dotatate | Novartis | Phase 2 | 52 |
| Anastrozole + Exemestane + Fulvestrant + Letrozole + Paclitaxel + Talimogene Laherparepvec + Tamoxifen + Nab paclitaxel + Gemcitabine + Carboplatin | Amgen | Phase 1 | 32 |
| Sacituzumab Govitecan | Gilead Sciences | Phase 2 | 51 |
| Anastrozole + Exemestane + Fulvestrant + Letrozole + Palbociclib + Tamoxifen | Pfizer | Phase 2 | 51 |
| Abexinostat Tosylate + Fulvestrant + Palbociclib | Pfizer | Phase 1 | 32 |
| Aromatase Inhibition Therapy | Bristol Myers Squibb | Pre-clinical | 22 |
| Pelareorep + Retifanlimab | Incyte | Phase 2 | 49 |
| Neratinib | Puma Biotechnology | Phase 2 | 44 |
| Ivermectin + Balstilmab + Pembrolizumab | Agenus | Phase 1/2 | 33 |
Other Products from Imugene
IMU-131 + Ramucirumab plus Paclitaxel + PembrolizumabPhase 2
44
IMU-131 + Cisplatin and either Fluorouracil (5-FU) or Capecitabine or Oxaliplatin and capecitabine.Phase 1/2
33
Azer-cel + Fludarabine + Cyclophosphamide + IL-2Phase 1
25
CF33-CD19 IT Monotherapy + CF33-CD19 IV Monotherapy + CF33-CD19 IT Combination + CF33-CD19 IV Combination + Blinatumomab + HydroxyureaPhase 1
25
CF33-hNIS + Pembrolizumab + Modified FOLFOXPhase 1
25